Financial toxicity in insured patients with multiple myeloma: A cross-sectional pilot study

The Lancet Haematology

Volumn 2, Issue 10, 2015, Pages e408-e416

  Huntington, Scott F ^a   Weiss, Brendan M ^a   Vogl, Dan T ^a   Cohen, Adam D ^a   Garfall, Alfred L ^a   Mangan, Patricia A ^a   Doshi, Jalpa A ^b   Stadtmauer, Edward A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; LENALIDOMIDE; THALIDOMIDE;

ADULT; AGED; ARTICLE; ASSESSMENT OF HUMANS; AUTOLOGOUS STEM CELL TRANSPLANTATION; COPING BEHAVIOR; COST CONTROL; CROSS-SECTIONAL STUDY; EMPLOYMENT STATUS; FEMALE; FINANCIAL TOXICITY; GENDER; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; ILLNESS BEHAVIOR; INCOME; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MEDICAID; MULTIPLE MYELOMA; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT REFUSAL; COST OF ILLNESS; ECONOMICS; MIDDLE AGED; PILOT STUDY; QUALITY OF LIFE; UNITED STATES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COST OF ILLNESS; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH CARE COSTS; HEALTH EXPENDITURES; HUMANS; INCOME; INSURANCE, HEALTH; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PILOT PROJECTS; QUALITY OF LIFE; UNITED STATES;

EID: 84955707575     PISSN: None     EISSN: 23523026     Source Type: Journal    
DOI: 10.1016/S2352-3026(15)00151-9     Document Type: Article

References (33)

1. Anderson KC. The 39th David A. Karnofsky Lecture: bench-tobedside translation of targeted therapies in multiple myeloma. J Clin Oncol 2012; 30: 445-52.
2. Kim MY, Sposto R, Swaika A, et al. Pharmacoeconomic implications of lenalidomide maintenance therapy in multiple myeloma. Oncology 2014; 87: 224-31.
3. Teitelbaum A, Ba-Mancini A, Huang H, et al. Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data. Oncologist 2013; 18: 37-45.
4. Light DW, Kantarjian H. Market spiral pricing of cancer drugs. Cancer 2013; 119: 3900-02.
5. Kantarjian HM, Fojo T, Mathisen M, et al. Cancer drugs in the United States: justum pretium-the just price. J Clin Oncol 2013; 31: 3600-04.
6. Kantarjian H, Rajkumar SV. Why are cancer drugs so expensive in the United States, and what are the solutions? Mayo Clin Proc 2015; 90: 500-04.
7. Mehta J, DuffSB, Gupta S. Cost effectiveness of bortezomib in the treatment of advanced multiple myeloma. Manag Care Interface 2004; 17: 52-61.
8. Brown RE, Stern S, Dhanasiri S, et al. Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales. Eur J Health Econ 2013; 14: 507-14.
9. Garrison LP Jr, Wang ST, Huang H, et al. The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment. Oncologist 2013; 18: 27-36.
10. Doss S, Hay N, Sutcliffe F. NICE guidance on bortezomib and thalidomide for first-line treatment of multiple myeloma. Lancet Oncol 2011; 12: 837-38.
11. Reece D, Kouroukis CT, Leblanc R, et al. Practical approaches to the use of lenalidomide in multiple myeloma: a Canadian consensus. Adv Hematol 2012; 2012: 621958.
12. Claxton G, Rae M, Panchal N, et al. Health benefits in 2013: moderate premium increases in employer-sponsored plans. Health Aff(Millwood) 2013; 32: 1667-76.
13. Hoadley J, Cubanski J, Hargrave E, Summer L. Medicare part D: a first look at plan offerings in 2014. Washington, DC: Kaiser Family Foundation; 2013. http://kaiserfamilyfoundation.files.wordpress.com/2013/10/8503-medicare-part-d-2014-first-look.pdf (accessed March 31, 2015).
14. Hurria A, Naylor M, Cohen HJ. Improving the quality of cancer care in an aging population: recommendations from an IOM report. JAMA 2013; 310: 1795-96.
15. Ubel PA, Abernethy AP, Zafar SY. Full disclosure-out-of-pocket costs as side effects. N Engl J Med 2013; 369: 1484-86.
16. Stump TK, Eghan N, Egleston BL, et al. Cost concerns of patients with cancer. J Oncol Pract 2013; 9: 251-57.
17. Zafar SY, Peppercorn JM, Schrag D, et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist 2013; 18: 381-90.
18. Bestvina CM, Zullig LL, Rushing C, et al. Patient-oncologist cost communication, financial distress, and medication adherence. J Oncol Pract 2014; 10: 162-67.
19. Zafar SY, McNeil RB, Thomas CM, et al. Population-based assessment of cancer survivors' financial burden and quality of life: a prospective cohort study. J Oncol Pract 2014; 11: 145-50.
20. Fenn KM, Evans SB, McCorkle R, et al. Impact of financial burden of cancer on survivors' quality of life. J Oncol Pract 2014; 10: 332-38.
21. Bansal A, Ramsey SD, Fedorenko CR, et al. Financial insolvency as a risk factor for mortality among patients with cancer. Proc Am Soc Clin Oncol 2015; 33 (suppl): abstr 6509.
22. de Souza JA, Yap BJ, Hlubocky FJ, et al. The development of a financial toxicity patient-reported outcome in cancer: the COST measure. Cancer 2014; 120: 3245-53.
23. De Souza JA, Wroblewski K, Yap BJ, et al. Grading financial toxicity based upon its impact of health quality of life (HRQol). Proc Am Soc Clin Oncol 2015; 33 (suppl): abstr 6618.
24. Schrag D, Naughton A, Kesselheim L, et al. Clinical trial participants' strategies for coping with prescription drug costs: a companion study to CALGB 80405. Proc Am Soc Clin Oncol 2009;27(suppl): abstr 9503.
25. Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011; 117: 4691-95.
26. Harris PA, Taylor R, Thielke R, et al: Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42: 377-81.
27. Dusetzina SB, Winn AN, Abel GA, et al. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol 2014; 32: 306-11.
28. Printz C. Drug parity legislation: states, organizations seek to make oral cancer drugs more affordable. Cancer 2014; 120: 313-14.
29. United States Census Bureau. Income and Poverty in the United States: 2013. http://www.census.gov/hhes/www/income (accessed March 31, 2015).
30. Warren JL, Harlan LC, Stevens J, et al. Multiple myeloma treatment transformed: a population-based study of changes in initial management approaches in the United States. J Clin Oncol 2013; 31: 1984-89.
31. Peppercorn J, Zafar SY, Houck K, Ubel P, Meropol NJ. Does comparative effectiveness research promote rationing of cancer care? Lancet Oncol 2014; 15: e132-38.
32. Streeter SB, Schwartzberg L, Husain N, et al. Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. J Oncol Pract 2011; 7: 46s-51s.
33. MacMillon Cancer Support. Cancer's hidden price tag: revealing the costs behind the illness. London, UK. http://www.macmillan.org.uk/Documents/GetInvolved/Campaigns/Costofcancer/Cancers-Hidden-Price-Tag-report-England.pdf (accessed July 24, 2015).